(12) United States Patent
`US 8,871,813 B2
`(10) Patent N0.:
`Sawa et al.
`
`(45) Date of Patent: *Oct. 28, 2014
`
`US008871813B2
`
`(54) AQUEOUS LIQUID PREPARATION
`CONTAINING
`
`2-AMINO-3-(4-BROMOBENZOYL)PHENYL-
`ACETIC ACID
`
`(71) Applicant: Senju Pharmaceutical Co., Ltd., Osaka
`(JP)
`
`(72)
`
`Inventors: Shirou Sawa, Hyogo (JP); Shuhei
`Fujita, Hyogo (JP)
`
`(73) Assignee: Senju Pharmaceutical Co., Ltd., Osaka
`(JP)
`
`( * ) Notice:
`
`Subject to any disclaimer, the term of this
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 0 days.
`
`This patent is subject to a terminal dis-
`claimer.
`
`(21) Appl.N0.: 14/261,720
`
`(22)
`
`Filed:
`
`Apr. 25, 2014
`
`(65)
`
`Prior Publication Data
`
`US 2014/0235721A1
`
`Aug. 21,2014
`
`Related US. Application Data
`
`(62) Division of application No. 14/165,976, filed on Jan.
`28, 2014, now Pat. No. 8,754,131, which is a division
`ofapplication No. 13/687,242, filed on Nov. 28, 2012,
`now Pat. No. 8,669,290, which is a division of
`application No. 13/353,653, filed on Jan. 19, 2012,
`now Pat. No. 8,497,304, which is a division of
`application No. 10/525,006, filed as application No.
`PCT/JP2004/000350 on Jan. 16, 2004, now Pat. No.
`8,129,431.
`
`(30)
`
`Foreign Application Priority Data
`
`Jan. 21, 2003
`
`(JP) ................................. 2003-012427
`
`(51)
`
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`
`Int. Cl.
`A01N37/18
`A61K 31/165
`A01N37/44
`A61K 31/24
`A01N37/10
`A61K 31/19
`(52) US. Cl.
`USPC ............ 514/619; 514/535; 514/570; 514/618
`(58) Field of Classification Search
`USPC .......................................... 514/619, 535, 570
`See application file for complete search history.
`
`(56)
`
`References Cited
`U.S. PATENT DOCUMENTS
`
`2,880,130 A
`2,880,138 A
`4,045,576 A
`4,683,242 A
`4,910,225 A
`
`3/1959 Johnson
`3/1959 Johnson
`8/1977 Welstead, Jr. et a1.
`7/1987 Poser
`3/1990 Ogawa et al.
`
`Page 1 of 9
`
`5,110,493 A
`5,475,034 A
`5,540,930 A
`5,558,876 A
`5,597,560 A
`5,603,929 A
`5,653,972 A
`5,942,508 A
`5,998,465 A
`6,071,904 A
`6,107,343 A
`6,162,393 A
`6,274,592 B1
`6,274,609 B1
`6,319,513 B1
`6,369,112 B1
`6,383,471 B1
`6,395,746 B1
`8,129,431 B2
`2001/0056098 A1
`2007/0082857 A1
`
`5/1992 Cherng-Chyi et a1.
`12/1995 Yanni et a1.
`7/1996 Guy et a1.
`9/1996 Desai et a1.
`1/1997 Bergamini et a1.
`2/1997 Desai et a1.
`8/1997 Desai et a1.
`8/1999 Sawa
`12/1999 Hellberg et a1.
`6/2000 Ali et a1.
`8/2000 Sallmann et a1.
`12/2000 De Bruiju et a1.
`8/2001 Sawa
`8/2001 Yasueda et a1.
`11/2001 Dobrozsi
`4/2002 Xia
`5/2002 Chen et a1.
`5/2002 Cagle et a1.
`3/2012 Sawa et a1.
`12/2001 Sawa
`4/2007 Sawa
`
`FOREIGN PATENT DOCUMENTS
`
`AU
`AU
`CA
`CA
`EP
`EP
`JP
`JP
`
`22042/88
`707 119
`2 013188
`2 383 971
`0 274 870
`0 306 984
`62-126124
`1-104023
`
`3/1989
`9/1995
`9/1990
`3/2001
`7/1988
`3/1989
`6/1987
`4/1989
`
`(Continued)
`
`OTHER PUBLICATIONS
`
`New Drugs in Japan, 2001, 2001 Edition, Published byYakuji Nippo
`Ltd., May 11, 2001, pp. 27-29, and its English translation of the
`material portions.
`
`(Continued)
`
`Primary Examiner 7 Layla Soroush
`
`(74) Attorney, Agent, or Firm 7 Wenderoth, Lind & Ponack,
`L.L.P.
`
`(57)
`
`ABSTRACT
`
`An aqueous liquid preparation of the present invention con-
`taining 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its
`pharmacologically acceptable salt or a hydrate thereof, an
`alkyl aryl polyether alcohol type polymer such as tyloxapol,
`or a polyethylene glycol fatty acid ester such as polyethylene
`glycol monostearate is stable. Since even in the case where a
`preservative is incorporated into said aqueous liquid prepa-
`ration,
`the preservative exhibits a sufiicient preservative
`effect for a long time, said aqueous liquid preparation in the
`form of an eye drop is useful for the treatment of blepharitis,
`conjunctivitis, scleritis, and postoperative inflammation.
`Also, the aqueous liquid preparation of the present invention
`in the form of a nasal drop is useful for the treatment of
`allergic rhinitis and inflammatory rhinitis (e.g. chronic rhini-
`tis, hypertrophic rhinitis, nasal polyp, etc.).
`
`27 Claims, No Drawings
`
`LUPIN EX 1003
`
`LUPIN EX 1003
`
`Page 1 of 9
`
`

`

`US 8,871,813 B2
`Page 2
`
`(56)
`
`References Cited
`
`FOREIGN PATENT DOCUMENTS
`
`JP
`JP
`JP
`JP
`JP
`JP
`WO
`WO
`WO
`WO
`WO
`WO
`
`02083323
`2-124819
`5-223052
`9-503791
`11-228404
`2002-308764
`94/05298
`94/15597
`96/14829
`00/59475
`01/15677
`02/13804
`
`3/1990
`5/1990
`8/1993
`4/1997
`8/1999
`10/2002
`3/1994
`7/1994
`5/1996
`10/2000
`3/2001
`2/2002
`
`OTHER PUBLICATIONS
`
`ISTA Pharmaceuticals, “New Drug Applications: Xibrom”, http://
`www.drugs.com/nda/Xibrom,040525.htrnt, accessed online Sep.
`19, 2007.
`Nolan et al., “The Topical Anti-Inflammatory and Analgesic Proper-
`ties of Bromfenic in Rodents”, Agents and Actions, vol. 25, No. 1-2,
`pp. 77-85, Aug. 1988.
`Corrected partial English translation of New Drugs in Japan, 2001,
`2001 Edition, Published by Yakuji Nippo Ltd., May 11, 2001, pp.
`27-29, previously submitted on Apr. 11, 2005.
`Complete English translation of New Drugs in Japan, 2001, 2001
`Edition, Published byYakuji Nippo Ltd., May 11, 2001, pp. 27-29.
`Notice of Opposition dated Feb. 19, 2009 issued by EPO in connec-
`tion with the corresponding European patent application and Oppo-
`sition.
`http://medical-dictionary.thefreedictionary.com/prophylactic
`accessed Dec. 15, 2009.
`H. Scott et al., “Comparing the Surface Chemical Properties and the
`Effect of Salts on the Cloud Point of a Conventional Nonionic
`Surfactant, Octoxynol 9 (Triton X-100), and of its Oligomer,
`Tyloxapol (Triton WR-1339)”, Journal of Colloid and Interface Sci-
`ence, vol. 205, pp. 496-502, 1998.
`Y. Hara, “Evaluation of New Drugs by Clinicians”, Clinics & Drug
`Therapy, vol. 19, No. 10, Oct. 2000, pp. 1-2.
`G. Smolin, M.D., “New Drugs in Ophthalmology”, International
`Ophthalmology Clinics, vol. 36, No. 2, 1996, pp. 1-9.
`ISTA News Release, XIBROMTM, Bromfenac Ophthalmic Solution,
`2007, p. 1.
`S. Prince et al., “Analysis of Benzalkonium Chloride and its
`Homologs: HPLC Versus HPCEl”, Journal of Pharmaceutical and
`Biomedical Analysis, vol. 19, pp. 877-882, 1999.
`M. Doughty, “Therapeutics: Medicines Update p18 Side-Effects of
`Anti-Epilepsy Drugs”, Optician, vol. 223, No. 5853, May 31, 2002,
`pp. 16-22.
`I. Reddy, Ph.D., “Ocular Therapeutics and Drug Delivery”,
`Technomics Publishing Co., Basel, pp. 42-43, 390, 1996.
`H. Schott, “Comparing the Surface Chemical Properties and the
`Effect of Salts on the Cloud Point of a Conventional Nonionic
`Surfactant, Octoxynol 9 (Triton X-100), and of its Oligomer,
`Tyloxapol (Triton WR-1339)”, Journal of Colloid and Interface Sci-
`ence, vol. 205, pp. 496-502, 1998.
`O. Regev, “Aggregation Behavior of Tyloxapol, a Nonionic
`Surfactant Oligomer, in Aqueous Solution”, Journal of Colloid and
`Interface Science, vol. 210, pp. 8-17, 1999.
`PDR 50th Edition 1996, Physicans’ Desk Reference, p. 469.
`
`PDR 54th Edition 2000, Physicans’ Desk Reference, pp. 486-487,
`491-492.
`
`V. A. Ostrovskii et al., “Acid-Base Properties of 5-Substituted
`Tetrazoles”, Khimiya Get. 800., pp. 412-416, 1981.
`LOTEMAXTM product
`brochure,
`Loteprednol
`Ophthalmic Suspension, 0.5%, pp. 1-16, Mar. 6, 1998.
`Webester’s New World Dictionary of the American Language, Sec-
`ond College Edition, “monohydrate”, Simon & Schuster, NY, p. 920,
`1982.
`
`Etabonate
`
`Pharmacopeia, R. S. Cook et al., “Edetic Acid”, pp. 177-179, JT
`Steward, “Sodium Metabisulfide”, pp. 451-453, 2000.
`Japanese
`Yakuji Nippo Limited, “Recent New Drugs 2001”,
`Pharmacopoeia 2001 Edition, pp. 27-29, May 2001 (English trans-
`lation).
`Sigma-Aldrich catalog, Biochemicals and Reagents for Life Science
`Research, p. 175, 2000.
`G. Patani et al., “Bioisosterism: A Rational Approach in Drug
`Design”, Chemical Reviews, vol. 96, No. 8, pp. 3147-3176, 1996.
`P. Deluca et al., “Interaction of Preservatives with Macromolecules
`IV, Binding of Quaternary Ammonium Compounds by Nonionic
`Agents”, Journal of the American Pharmaceutical Association, vol.
`49, No. 7, pp. 430-437, Jul. 1960.
`D. Guttman et al., “Solubilization of Anti-Inflammatory Steroids by
`Aqueous Solutions of Triton WR-1339”, Journal of Pharmaceutical
`Sciences, vol. 50, No. 4, pp. 305-307, Apr. 1961.
`T. Fan et al., “Determination of Benzalkonium Chloride in
`Ophthalmic Solutions Containing Tyloxapol by Solid-Phase Extrac-
`tion and Reversed-Phase High-Performance Liquid Chromatogra-
`phy”, Journal ofPharmaceutical Sciences, vol. 82, No. 11, pp. 1172-
`1174, Nov. 1993.
`FDA Website search of Orange Book (Patent and Exclusivity Search
`Results): Approved Drug Products with Therapeutic Equivalence
`Evaluations; Search Results for N203168, 2014.
`FDA website search of Orange Book (Detail Record Search):
`Approved Drug Products with Therapeutic Equivalence Evaluations,
`Search Results for N203168, 2014.
`Remington: The Science and Practice of Pharmacy, 20’” Edition,
`“Boric Acid”, Lippincoh, Williams, Baltimore MD, p. 1041, 2000.
`PDR 52nd Edition 1998, Physicans’ Desk Reference, “Duract”,
`Method Economics Co., Montrale, NJ, pp. 3035-3037.
`ALREXTM product package, Loteprednol Etabonate, Ophthalmic
`Suspension, 0.2%, pp. 1-13, 1998.
`XIBROMTM product package, Bromfenac Ophthalmic Solution,
`0.09%, pp. 3-6, 2000.
`Bromday product package, Bromfenac Ophthalmic Solution, 0.09%,
`pp. 4-8, 1997.
`PROLENSATM product package, Bromfenac Ophthalmic Solution,
`0.07%, pp. 4-9, 2013.
`PDR 54 Edition 2000, Physicans’ Desk Reference, pp. 489-491,
`TOBRADEX®, Tobramycin and Dexamethasone Ophthalmic Sus-
`pension and Ointment.
`FDA website description of VOLTAREN, Diclofenac Sodium,
`Ophthalmic Solution, 0.1%, pp. 1-2, 1991.
`The United States Pharmacopeia, The National Formulary, USP 24,
`NF 19, pp. 1809-1813,1864-1866,2000.
`Dorset & Baber, Webster’s New Twentieth Century Dictionary, Sec-
`ond Edition, “Ophthalmic” and “Ophthalmitic” p. 1254, 1979.
`BRONUCK® news
`release, Bromfenac
`Sodium Hydrate
`Ophthalmic Solution, p. 1, 2005.
`
`Page 2 of 9
`
`Page 2 of 9
`
`

`

`US 8,871,813 B2
`
`1
`AQUEOUS LIQUID PREPARATION
`CONTAINING
`
`2-AMINO-3-(4-BROMOBENZOYL)PHENYL-
`ACETIC ACID
`
`2
`
`preservative effect of benzalkonium chloride and other qua-
`ternary ammonium compounds.
`
`Disclosure Of The Invention
`
`TECHNICAL FIELD
`
`The present invention relates to an aqueous liquid prepa-
`ration containing 2-amino-3-(4-bromobenzoyl)phenylacetic
`acid or a pharmacologically acceptable salt thereof or a 10
`hydrate thereof. More particularly,
`the present
`invention
`relates to an aqueous liquid preparation containing 2-amino-
`3-(4-bromobenzoyl)phenylacetic acid or a pharmacologi-
`cally acceptable salt thereof or a hydrate thereof and an alkyl
`aryl polyether alcohol type polymer or a polyethylene glycol
`fatty acid ester.
`
`15
`
`BACKGROUND ART
`
`Benzoylphenylacetic acid derivatives including bromfenac
`(generic name) of formula (I):
`
`20
`
`o
`
`NH2
`
`0 0 COOH
`
`Br
`
`25
`
`50
`
`of which chemical name is 2-amino-3-(4-bromobenzoyl) 30
`phenylacetic acid are known as disclosed in JP-A-23052/
`1977 and its corresponding US. Pat. No. 4,045,576.
`2-Amino-3-(4-bromobenzoyl)phenylacetic acid, its pharma-
`cologically acceptable salt and a hydrate thereofare known as
`a non-steroidal anti-inflammatory agent, and they are effec- 35
`tive against inflammatory diseases of anterior or posterior
`segment of the eye, such as blepharitis, conjunctivitis, scleri-
`tis, and postoperative inflammation in the field of ophthal-
`mology, and its sodium salt has been practically used in the
`form of eye drops (“New Drugs in Japan, 2001”, 2001 Edi-
`tion, Published by Yakuji Nippo Ltd., May 11, 2001, p. 40
`27-29).
`The eye drop as mentioned above is designed to stabilize
`2-amino-3-(4-bromobenzoyl)phenylacetic acid by means of
`addition of a water-soluble polymer (e.g. polyvinylpyrroli-
`done, polyvinyl alcohol, etc.) and a sulfite (e.g. sodium 45
`sulfite, potassium sulfite, etc.) (Japanese patent No. 2,683,
`676 and its corresponding US. Pat. No. 4,910,225).
`In addition, as an eye drop other than the above-mentioned
`one, Japanese patent No. 2,954,356 (corresponding to US.
`Pat. Nos. 5,603,929 and 5,653,972) discloses a stable oph-
`thalmic composition which comprises incorporating an anti-
`bacterial quaternary ammonium polymer and boric acid into
`an acidic ophthalmic agent. The acidic agent described
`therein includes, for example, 2-amino-3-(4-bromobenzoyl)
`phenylacetic acid.
`Further, in Japanese patent No. 2,954,356, there is the 55
`following description-“Benzalkonium chloride is a widely
`used preservative in ophthalmic solutions. However, benza-
`lkonium chloride and other quaternary ammonium com-
`pounds are generally considered to be incompatible with
`ophthalmic compositions of drugs with acidic groups, such as
`nonsteroidal anti-inflammatory drugs. These preservatives
`lose their ability to function as they form complexes with the
`charged drug compounds”.
`In these prior art references, there is no disclosure that alkyl
`aryl polyether alcohol type polymers or polyethylene glycol
`fatty acid esters are able to stabilize an aqueous liquid prepa-
`ration of 2-amino-3-(4-bromobenzoyl) phenylacetic acid or
`its pharmacologically acceptable salt, and inhibit decrease in
`
`60
`
`65
`
`It is an object of the present invention to provide an aque-
`ous liquid preparation comprising 2-amino-3-(4-bromoben-
`zoyl) phenylacetic acid or a pharmacologically acceptable
`salt thereof or a hydrate thereof, which is stable within a pH
`range giving no irritation to eyes and in which, when a pre-
`servative such as benzalkonium chloride is incorporated
`therein, preservative effect of the preservative does not sub-
`stantially deteriorate.
`Another object of the invention is to provide a method for
`stabilizing an aqueous liquid preparation of 2-amino-3-(4-
`bromobenzoyl)phenylacetic acid or a pharmacologically
`acceptable salt thereof or a hydrate thereof.
`Further object of the invention is to provide an aqueous
`liquid preparation comprising 2-amino-3-(4-bromobenzoyl)
`phenylacetic acid or a pharmacologically acceptable salt
`thereof or a hydrate thereof and a preservative wherein, when
`specifically a quaternary ammonium salt such as benzalko-
`nium chloride is incorporated as a preservative, decrease in
`preservative effect of said preservative is inhibited.
`As a result of various studies, the inventors of the present
`invention have found that, by adding, for example, an alkyl
`aryl polyether alcohol type polymer such as tyloxapol, or a
`polyethylene glycol fatty acid ester such as polyethylene
`glycol monostearate to an aqueous liquid preparation of
`2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharma-
`cologically acceptable salt thereof or a hydrate thereof, the
`aqueous solution becomes stable within a pH range giving no
`irritation to eyes, and change ofthe 2-amino-3-(4-bromoben-
`zoyl)phenylacetic acid over time can be inhibited, and fur-
`thermore, when the aqueous solution contains a preservative,
`deterioration in the preservative effect of said preservative
`can be inhibited for a long period oftime. The inventors ofthe
`present invention have further studied extensively and com-
`pleted the present invention.
`Namely, the present invention relates to:
`(1) An aqueous liquid preparation comprising 2-amino-3-(4-
`bromobenzoyl)phenylacetic acid or a pharmacologically
`acceptable salt thereof or a hydrate thereof, and an alkyl
`aryl polyether alcohol type polymer or a polyethylene gly-
`col fatty acid ester,
`(2) The aqueous liquid preparation according to the above (1),
`wherein the alkyl aryl polyether alcohol type polymer has
`a polymerization degree of 3 to 10, the alkyl contains 1 to
`18 carbon atoms, the aryl is a phenyl residue, and the
`polyether
`alcohol
`is
`represented by the
`formula
`O(CH2CH20)XH in which X is an integer of 5 to 100,
`(3) The aqueous liquid preparation according to the above (1)
`or (2), wherein the alkyl aryl polyether alcohol type poly-
`mer is tyloxapol,
`(4) The aqueous liquid preparation according to the above (1),
`wherein the carbon number of the fatty acid in the polyeth-
`ylene glycol fatty acid ester is 12 to 18,
`(5) The aqueous liquid preparation according to the above (1)
`or (4), wherein the polyethylene glycol fatty acid ester is
`polyethylene glycol monostearate,
`(6) The aqueous liquid preparation according to any one of
`the above (1) to (3), wherein the concentration of the alkyl
`aryl polyether alcohol type polymer is selected from a
`range of minimum concentration of 0.01 w/v to maximum
`concentration of 0.5 w/v
`(7) The aqueous liquid preparation according to any one of
`the above (1), (2) or (4), wherein the concentration of the
`polyethylene glycol fatty acid ester is selected from a range
`of minimum concentration of 0.02 w/v % to maximum
`concentration of 0.1 w/v %,
`(8) The aqueous liquid preparation according to any one of
`the above (1) to (7), wherein the concentration of the
`
`Page 3 of 9
`
`Page 3 of 9
`
`

`

`US 8,871,813 B2
`
`3
`2-amino-3-(4-bromobenzoyl)phenylacetic acid or a phar-
`macologically acceptable salt thereof or a hydrate thereof
`is 0.01 to 0.5 w/v,
`(9) The aqueous liquid preparation according to any one of
`the above (1) to (8), wherein benzalkonium chloride is
`contained as a preservative,
`(10) The aqueous liquid preparation according to anyone of
`the above (1 ) to (9), wherein the pharmacologically accept-
`able salt of2-amino-3-(4-bromobenzoyl)phenylacetic acid
`is a sodium salt,
`(11) The aqueous liquid preparation according to any one of
`the above (1) to (10), wherein the pH of the aqueous liquid
`preparation is within a range of 7 to 9,
`(12) The aqueous liquid preparation according to the above
`(11), wherein the pH of the aqueous liquid preparation is
`within a range of7.5 to 8.5,
`(13) The aqueous liquid preparation according to any one of
`the above (1) to (12), wherein the aqueous liquid prepara-
`tion is an eye drop,
`(14) The aqueous liquid preparation according to any one of
`the above (1) to (12), wherein the aqueous liquid prepara-
`tion is a nasal drop,
`(15) An eye drop comprising sodium 2-amino-3-(4-bro-
`mobenzoyl)phenylacetate hydrate and 0.01 to 0.5 w/v % of
`tyloxapol,
`(16) An eye drop comprising sodium 2-amino-3-(4-bro-
`mobenzoyl) phenylacetate hydrate and 0.02 to 0.1 w/v of
`polyethylene glycol monostearate,
`(17) A method for stabilizing 2-amino-3-(4-bromobenzoyl)
`phenylacetic acid or a pharmacologically acceptable salt
`thereof or a hydrate thereof in an aqueous liquid prepara-
`tion, which comprises incorporating tyloxapol or polyeth-
`ylene glycol monostearate into an aqueous liquid prepara-
`tion
`containing
`2-amino-3-(4-bromobenzoyl)
`phenylacetic acid or a pharmacologically acceptable salt
`thereof or a hydrate thereof, and
`(18) A method for inhibiting decrease in preservative effect of
`a preservative in an aqueous liquid preparation of 2-amino-
`3-(4-bromobenzoyl)phenylacetic acid or a pharmacologi-
`cally acceptable salt thereof or a hydrate thereof, which
`comprises incorporating tyloxapol or polyethylene glycol
`monostearate into an aqueous liquid preparation contain-
`ing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a
`pharmacologically acceptable salt thereof or a hydrate
`thereof and a preservative.
`According to the present invention, a stable aqueous liquid
`preparation containing 2-amino-3-(4-bromobenzoyl)pheny-
`lacetic acid or a pharmacologically acceptable salt thereof or
`a hydrate thereof can be prepared by incorporating an alkyl
`aryl polyether alcohol type polymer such as tyloxapol, or a
`polyethylene glycol fatty acid ester such as polyethylene
`glycol monostearate into an aqueous liquid preparation con-
`taining 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a
`pharmacologically acceptable salt
`thereof or a hydrate
`thereof. Also, an aqueous liquid preparation of the present
`invention, wherein a preservative is incorporated, has a suf-
`ficient preservative effect.
`Therefore, the aqueous liquid preparation of the present
`invention is advantageously used as an eye drop for the treat-
`ment of, for example, blepharitis, conjunctivitis, scleritis, and
`postoperative inflammation. In addition, such aqueous liquid
`preparation can be used as a nasal drop for the treatment of,
`for example, allergic rhinitis and inflammatory rhinitis (e.g.
`chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).
`The pharmacologically acceptable salt of 2-amino-3-(4-
`bromobenzoyl) phenylacetic acid includes, for example, an
`alkali metal salt such as sodium salt and potassium salt, and
`an alkaline earth metal salt such as calcium salt and magne-
`sium salt, among which sodium salt is especially preferable.
`2-Amino-3-(4-bromobenzoyl)phenylacetic acid and its
`pharmacologically acceptable salt can be prepared according
`to the method as described in JP-A-23052/1977 (correspond-
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`Page 4 of 9
`
`4
`
`ing to US. Pat. No. 4,045,576) or by a similar method thereof.
`These compounds can be obtained as their hydrate depending
`on synthetic conditions and recrystallization conditions. The
`hydrate includes 1/2 hydrate,
`1 hydrate, and 3/2 hydrate,
`among which 3/2 hydrate is preferable.
`In the aqueous liquid preparation of the present invention,
`the content
`(concentration range) of 2-amino-3-(4-bro-
`mobenzoyl)phenylacetic acid or a pharmacologically accept-
`able salt thereof or a hydrate thereof is usually about 0.01 to
`0.5 w/v %, preferably about 0.05 to 0.2 w/v %, especially
`about 0.1 w/v %, and it is preferable to appropriately vary the
`content depending on the purpose of use and the degree of
`disease to be treated.
`The carbon number of the alkyl in the an alkyl aryl poly-
`ether alcohol type polymer which is a non-ionic surfactant
`used as a stabilizer for 2-amino-3-(4-bromobenzoyl)pheny-
`lacetic acid or a pharmacologically acceptable salt thereof or
`a hydrate thereof is approximately 1 to 18. Specifically, the
`alkyl group includes, for example, methyl, ethyl, propyl, iso-
`propyl, cyclopropyl, butyl,
`isobutyl, sec-butyl,
`tert-butyl,
`cyclobutyl, pentyl, isopentyl, neopentyl, tert-pentyl, 1-ethyl-
`propyl, 4-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbu-
`tyl, 1,2-dimethylbutyl, 2-ethylbutyl, cyclopentyl, hexyl,
`cyclohexyl, heptyl,
`isoheptyl,
`octyl,
`isooctyl, nonyl,
`isononyl, decyl, isodecyl, undecyl, isoundecyl, dodecyl, isod-
`odecyl, tridecyl, isotridecyl, tetradecyl, isotetradecyl, penta-
`decyl, isopentadecyl, hexadecyl, isohexadecyl, heptadecyl,
`isoheptadecyl, octadecyl, isooctadecyl, and isomers thereof,
`among which octyl and its isomer (e.g. isooctyl, sec-octyl,
`1-methylheptyl, 1-ethylhexyl, 2-ethylhexyl, 1-propylpentyl,
`1,5-dimethylhexyl, 1,1,3,3-tetramethylbutyl, etc.) are prefer-
`able, and 1,1,3,3-tetramethylbutyl which is an isomer of octyl
`groups is especially preferable.
`The aryl in the alkyl aryl polyether alcohol type polymer
`can be preferably a phenyl residue. The polyether alcohol can
`be represented by the formula O(CH2CH2CHZO)XH in which
`X is an integer of 5 to 100, preferably 5 to 30, more preferably
`8 to 10. The average polymerization degree is preferably
`about 3 to 10.
`Among the above-mentioned alkyl aryl polyether alcohol
`type polymers, tyloxapol having the following formula is
`especially preferable.
`
`
`
`m C(CH3)3
`
`C(CH3)3
`R : (CHZCHZO) xH
`x : 8-10
`m < 6
`
`The fatty acid of the polyethylene glycol fatty acid ester
`which is a non-ionic surfactant used as a stabilizer for
`2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharma-
`cologically acceptable salt thereof or a hydrate thereof can be
`preferably a fatty acid having the carbon number of 12 to 18.
`Specific examples of such polyethylene glycol fatty acid
`esters are polyethylene glycol monostearate (e.g. polyoxyl 8
`stearate, polyoxyl 40 stearate, etc.), polyethylene glycol
`monolaurate, polyethylene glycol monooleate, polyethylene
`glycol diisostearate, polyethylene glycol dilaurate, polyeth-
`ylene glycol dioleate, and the like. Among these compounds,
`polyethylene glycol monostearate is preferable, and polyoxyl
`
`Page 4 of 9
`
`

`

`US 8,871,813 B2
`
`5
`40 stearate is especially preferable. The polyoxyl 40 stearate
`is a monostearic acid ester of an ethylene oxide condensed
`polymer, and can be represented by the formula C17H35COO
`(CH2CHzO)nH which is a non-ionic surfactant and n is about
`40.
`
`Although the content (concentration range) of the alkyl
`aryl polyether alcohol type polymer in the aqueous liquid
`preparation of the present invention depends on the kind of
`compounds used, the minimum concentration is about 0.01
`w/v and the maximum concentration is about 0.5 w/v %. With
`respect to the tyloxapol content (concentration range), for
`example, the minimum content is about 0.01 w/v %, 0.02 w/v
`or 0.03 w/v %, and the maximum content is about 0.05 w/v %,
`0.1 w/v %, 0.3 w/v % or 0.5% w/v, and preferably the mini-
`mum content is about 0.02 w/v % and the maximum content
`is about 0.05 w/v %.
`Although the content (concentration range) of the polyeth-
`ylene glycol fatty acid ester in the aqueous liquid preparation
`of the present invention depends on the kind of compounds
`used, it is within a range of about 0.02 w/v % of minimum
`concentration to about 0.1 w/v % ofmaximum concentration.
`
`For example, the content (concentration range) of polyethyl-
`ene glycol monostearate is within a range ofabout 0.02 w/v of
`minimum content to about 0.1 w/v of maximum content, and
`preferably within a range of about 0.02 w/v % of the mini-
`mum content to about 0.05 w/v of the maximum content.
`The incorporation ratio of tyloxapol in the aqueous liquid
`preparation ofthe invention is within a range ofthe minimum
`content of about 0.1 or 0.2 part by weight to the maximum
`content ofabout 0.5, 1, 3 or 5 parts by weight, relative to 1 part
`by weight of 2-amino-3-(4-bromobenzoyl)phenylacetic acid
`or its pharmacologically acceptable salt or a hydrate thereof.
`The incorporation ratio of polyethylene glycol monostear-
`ate in the aqueous liquid preparation of the present invention
`is within a range ofthe minimum content of about 0.2 part by
`weight to the maximum content of about 0.5 or 1 part by
`weight, relative to 1 part by weight of 2-amino-3-(4-bro-
`mobenzoyl)phenylacetic
`acid or
`its pharmacologically
`acceptable salt or a hydrate thereof.
`The preservative used in the present invention includes, for
`example, quaternary ammonium salts (e.g. benzalkonium
`chloride, benzethonium chloride, etc.), chlorhexidine glu-
`conate, and the like, among which benzalkonium chloride is
`especially preferable.
`Further, so long as the purpose of the present invention is
`achieved, conventional various additives such as isotonics,
`buffers, thickners, stabilizers, chelating agents, pH control-
`ling agents, perfumes and the like may be appropriately added
`to the aqueous liquid preparation ofthe present invention. The
`isotonics include sodium chloride, potassium chloride, glyc-
`erine, mannitol, sorbitol, boric acid, glucose, propylene gly-
`col and the like. The buffers include, for example, phosphate
`buffer, borate buffer, citrate buffer, tartarate buffer, acetate
`buffer, boric acid, borax, amino acids, and the like. The thick-
`ners include polyvinylpyrrolidone, carboxymethylcellulose,
`carboxypropylcellulose,
`hydroxyethylcellulose,
`hydrox-
`ypropylcellulose, hydroxypropylmethylcellulose, polyvinyl
`alcohol, sodium polyacrylate, and the like. The stabilizers
`include sulfites such as sodium sulfite and the like. The chelat-
`ing agents include sodium edetate, sodium citrate, condensed
`sodium phosphate and the like. The pH controlling agents
`include hydrochloric acid, sodium hydroxide, phosphoric
`acid, acetic acid and the like. The perfumes include 1-men-
`thol, borneol, camphor, Eucalyptus oil, and the like.
`With respect to the concentrations of the above various
`additives in the aqueous liquid preparation of the present
`invention,
`the isotonic is incorporated into an osmotic pressure ratio of
`about 0.8 to 1.2, and the concentrations of the buffer and the
`thickner to be added are about 0.01 to 2 w/v and 0.1 to 10 w/v
`%, respectively.
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`6
`The pH of the aqueous liquid preparation of the present
`invention is adjusted to about 6 to 9, preferably about 7 to 9,
`especially about 7.5 to 8.5.
`So long as the purpose of the present invention is achieved,
`other same or different kind of active ingredients may be
`appropriately added.
`The aqueous liquid preparation ofthe present invention can
`be prepared by per se known method or according to the
`method as described in the Japanese Pharmacopoeia. 14th
`Edition, General Rules for Preparations, Solutions or Oph-
`thalmic solutions.
`The aqueous liquid preparation ofthe present invention can
`be applied to warm-blooded animals such as human, rat,
`mouse, rabbit, cow, pig, dog, cat, and the like.
`The aqueous liquid preparation ofthe present invention can
`be prepared easily by dissolving the above-mentioned com-
`ponents in, for example, distilled water or sterile purified
`water. For example, the aqueous liquid preparation in the
`form of an eye drop can be used for the treatment of inflam-
`matory diseases in anterior or posterior segment of the eye
`such as blepharitis, conjunctivitis, scleritis, postoperative
`inflammation, and the like. The dose of the aqueous liquid
`preparation containing 0.1 w/v of sodium 2-amino-3-(4-bro-
`mobenzoyl) phenylacetate hydrate is, for example, adminis-
`tered to an adult 3 to 6 times daily in an amount of 1 to 2 drops
`per one time. Depending on the degree of diseases, frequency
`of dosing is appropriately controlled.
`
`BEST MODE FOR CARRYING OUT THE
`INVENTION
`
`The present invention is illustrated by way ofthe following
`Experimental Examples and Working Examples, but it is not
`restricted by these Examples.
`
`EXPERIMENTAL EXAMPLE 1
`
`Stability test of sodium
`2-amino-3-(4 -bromobenzoyl)phenylacetate
`
`Four eye drops of sodium 2-amino-3-(4-bromobenzoyl)
`phenylacetate comprising the components as shown in Table
`1 were prepared, filled respectively into a polypropylene con-
`tainer and subjected to stability test at 60° C.
`
`TABLE 1
`
`Component
`
`Comparison
`Example 1
`
`0.1 g
`
`Sodium 2-amino-3-(4-
`bromobenzoyl)—
`phenylacetate
`1.5 g
`Boric acid
`Benzalkonium chloride 0.005 g
`Polysorbate 80
`0.15 g
`Polyoxyl 40 stearate 7
`Tyloxapol
`7
`Sterile purified water
`q.s.
`Total volume
`100 mL
`pH
`7.0
`Remaining rate
`51.3
`(%) at 60° C.
`after 4 weeks
`
`A-Ol
`
`A-02
`
`A-03
`
`0.1 g
`
`0.1 g
`
`0.1 g
`
`1.5 g
`1.5 g
`0.005 g
`0.005 g
`7
`7
`0.15 g 7
`7
`0.15 g
`q.s.
`q.s.
`100 mL
`100 mL
`7.0
`7.0
`63 .7
`73.8
`
`1.5 g
`0.005 g
`7
`7
`0.02 g
`q.s
`100 mL
`7.0
`89.6
`
`indicates
`The remaining rate (%) in the above Table 1
`values obtained by correcting moisture vaporization from the
`container. As is apparent from the Table 1, stability test was
`carried out under the conditions of pH 7.0 at 60° C. for 4
`weeks, and sodium 2-amino-3-(4-bromobenzoyl)phenylac-
`etate in each eye drop was stable in the order of tyloxapol-
`containing preparation>polyoxyl 40 stearate-containing
`preparation>polysorbate 80-containing preparation.
`
`Page 5 of 9
`
`Page 5 of 9
`
`

`

`US 8,871,813 B2
`
`7
`Further, with respect to eye drops containing tyloxapol
`(compositions A-02 and A-03), sodium 2-amino-3-(4-bro-
`mobenzoyl)phenylacetate in composition A-03 containing
`002 W/V 0f tyloxapol is more stable than that in composition
`A'02 containing 015 W/V % 0f tyloxapol.
`EXPERIMENTAL EXAMPLE 2
`
`Stability test of sodium
`2-am1no-3-(4-bromobenzoyl)phenylacetate
`
`5
`
`10
`
`8
`compositions A-04, A-05, A-06, A-07 and A-08 containing
`0.02 w/v t, 0.03 w/v and 0.05 w/v % of tyloxapol or 0.02 w/v
`% and 0.05 w/v % of polyoxyl 40 stearate is not less than 90
`after storage at 60° C. for 4 weeks, which indicates that those
`compositions have sufficient stability for eye drops.
`
`EXPERIMENTAL EXAMPLE 3
`
`Preservative Effect Test ofAqueous Liquid
`Preparation Containing Sodium
`2-amino-3-(4-bromobenzoyl)phenylacetate
`
`Five eye drops of sodium 2-amino-3-(4-bromobenzoyl)
`phenylacetate comprising the components as shown in Table
`2 were prepared, filled respectively into a polypropylene con-
`Preservative effect test of compositions A-04, A-05 and
`tainer and preserved at 600 C. for 4 weeks, and then the
`content of 2-amino-3-(4-bromobenzoyl)phenylacetic acid 15 A-07 of Experimental Example 2 was carried out against
`and the pH in each eye drop were measured.
`Staphylococcus aureus (hereinafter referred to as S. aureus),
`TABLE 2
`
`Components
`
`Sodium 2-aInino-3-(4—
`bromobenzoyl)phenyl-
`acetate
`Boricacid
`Borax
`Benzalkonium chloride
`Polysorbate 80
`Tyloxapol
`Polyoxyl40 stearate
`Polyvinyl-
`pyrrolidone (K-30)
`Sodium edetate
`Sodium hydroxide
`Sterile purified water
`Total volume
`pH
`60° C.,
`4 weeks
`
`Remaining
`rate (%)
`pH
`
`A-04
`
`0.1 g
`
`A-05
`
`0.1 g
`
`A-06
`
`0.1 g
`
`A-07
`
`0.1 g
`
`A-08
`
`0.1 g
`
`1.1 g
`1.1 g
`1.1 g
`1.1 g
`1.1 g
`1.1 g
`1.1 g
`1.1 g
`1.1 g
`1.1 g
`
`0.005 g
`0.005 g
`0.005 g
`0.005 g
`0.005 g
`
`0.02 g
`7
`2.0 g
`
`0.02 g
`q.s.
`q.s.
`100 mL
`8.17
`92.6
`
`0.05 g
`7
`2.0 g
`
`0.02 g
`q.s.
`q.s.
`100 mL
`8.16
`90.9
`
`0.03 g
`7
`2.0 g
`
`0.02 g
`q.s.
`q.s.
`100 mL
`8.15
`92.0
`
`7
`0.02 g
`2.0 g
`
`0.02 g
`q.s.
`q.s.
`100 mL
`8.19
`93.4
`
`7
`0.05 g
`1.0 g
`
`0.02 g
`q.s.
`q.s.
`100 mL
`8.19
`93.1
`
`8.15
`
`8.16
`
`8.15
`
`8.13
`
`8.14
`
`Table 2 shows the remaining rate and the pH of sodium
`2-amino-3-(4-bromobenzoyl